| Autor: |
Bui, Matthew H, Zisman, Amnon, Pantuck, Allan J, Han, Ken-ryu, Wieder, Jeff, Belldegrun, Arie S |
| Zdroj: |
Expert Review of Anticancer Therapy; December 2001, Vol. 1 Issue: 4 p565-575, 11p |
| Abstrakt: |
Renal cell carcinoma is the most common cancer in the kidney, affecting nearly 30,000 Americans every year and is associated with over 12,000 deaths annually. If detected early, renal cell carcinomas can be cured surgically. However, once metastatic disease develops the prognosis for long-term survival is poor. Unfortunately, one-third of patients have metastatic disease at the time of diagnosis and approximately 50% of the patients undergoing surgical resection for less advanced disease eventually relapse. This review examines the clinical and molecular prognostic tools currently available or under investigation for kidney cancer. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
